Insight journal - Company

Genmab: Partnering activity 2009-2014

Posted on 29 September 2014

Tags: , ,

Genmab, a top big biotech company, headquartered in Denmark is one of the leaders today in the human antibody therapeutics market for cancer treatment. The company’s first marketed antibody was ofatumumab. Genmab seeks partners for innovative product candidates and technologies to support its therapy focus areas such as cancer, autoimmune diseases, inflammation, CNS and infectious diseases.

Our partnering activity article looks in detail the deals entered into by Genmab and the trends it follows.

The following figure shows the level of Genmab partnering deal announcements since 2009.

Figure 1: Genmab partnering deals 2009-2014

Figure 1: Genmab partnering deals 2009-2014

Figure 1: Genmab partnering deals 2009-2014

 Source: Current Agreements, 2014

 

From the figure, it is interesting to note that Genmab is active every other year since 2010, partnering with big pharma companies like Amgen, GSK, Janssen, Seattle Genetics, Roche, Lundbeck for products and technologies.

Genmab has recently partnered with big biotech and pharma companies like Seattle Genetics, Eli Lilly, ADC Therapeutics for ADC’s in their cancer research treatments. These compounds are in their early stage development (discovery/ preclinical) thus providing the right for Genmab to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments

The following table provides an overview of the partnering deals announced by Genmab based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal. See: Report: Partnering Agreements with Genmab 2009-2014

Figure 2: Genmab partnering deals by therapy area 2009-2014

Figure 2: Genmab partnering deals by therapy area 2009-2014

Figure 2: Genmab partnering deals by therapy area 2009-2014

 Source: Current Agreements, 2014

Further analysis of these deals shows that Genmab has a preference for collaborative R&D, licensing and development deals similar to many other top pharmaceutical or big biotech companies.

The following table provides an overview of the partnering deals announced by Genmab based on deal type disclosed.

Figure 3: Genmab partnering deals by deal type 2009-2014

Figure 3: Genmab partnering deals by deal type 2009-2014

Figure 3: Genmab partnering deals by deal type 2009-2014

Source: Current Agreements, 2014

Genmab is focussed on in-licensing and out-licensing opportunities. The company partners at early stages of development to benefit from the full commercial potential of the products in development.

The following table provides an overview of the partnering deals announced by Genmab based on stage of development at signature. 

Figure 4: Genmab partnering by stage of development 2009-2014

Figure 4: Genmab partnering by stage of development 2009-2014

Figure 4: Genmab partnering by stage of development 2009-2014

 

Source: Current Agreements, 2014

In July 2012, Genmab entered into a research collaboration with Janssen Biotech to create bi-specific antibodies using Genmab’s DuoBody technology. The deal is valued at $1753.5 million that includes upfront, licensing and continued milestone payments.

The following provides a summary of the top deals by headline value.

Figure 5: Top Genmab partnering deals by headline value 2009-2014

Figure 5: Top Genmab partnering deals by headline value 2009-2014

Figure 5: Top Genmab partnering deals by headline value 2009-2014

Source: Current Agreements, 2014

 

Genmab partnering at Current Agreements

View all partnering deals for Genmab: 2014 | 2013 | 2012 | 2011 | 2010 | 2009

Full details on each deal can be found at CurrentAgreements (subscription required)

Or purchase report: Report: Partnering Agreements with Genmab 2009-2014

More 

Summary profile data for Genmab

Partnering interests for Genmab

No M&A activity for Genmab

Available reports from Current Partnering

Report: Partnering Agreements with Genmab 2009-2014

Report: Partnering Deals and Alliances with Big Biotech

Available resources for deal coverage for Genmab

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Genmab company profile, recent partnering, M&A and financing news and articles

 

Related

Report:Finding Biopharma Licensing and Collaboration Partners

View: CP Insight’s Partnering Scorecard – view top life science partnering deals by value

View: CP Insight’s M&A Scorecard – view top life science M&A deals by value

View: CP Insight’s Deal Metrics – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

 

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply